CCI Clears Merger of Quality Care India with Aster DM Healthcare

The Competition Commission of India (CCI) has approved the merger of Quality Care India Ltd. (QCIL) into Aster DM Healthcare Ltd. The transaction is structured as a scheme of amalgamation. Once the merger is completed, the combined entity will be renamed Aster DM Quality Care Ltd.

As of 9:31 am on April 16, 2025, Aster DM Healthcare share price was trading at ₹498.85, up 1.92% for the day, with a 16.57% gain over the past six months and a 4.06% decline over the past year.. Its market capitalisation stood at ₹24,551.07 crore.

Shareholding and Stake Changes

Ahead of the merger, Aster DM Healthcare will acquire a 5% stake in Quality Care India from existing investors – BCP Asia II TopCo IV Pte. Ltd. and Centella Mauritius Holdings Ltd. This acquisition will be made through Aster’s primary share issuance. Following the merger, shareholders of Quality Care India, including BCP Asia, Centella, and certain minority investors, will receive equity in the combined entity. Centella will hold less than 10% stake and will not have control rights.

Ownership and Background of Entities

Quality Care India is an unlisted company backed by Blackstone and TPG. BCP Asia is affiliated with Blackstone, while Centella is owned by TPG Group. QCIL operates multiple healthcare facilities across India under brand names such as CARE Hospitals, KIMS Health, and Evercare.

Aster DM Healthcare is part of the Aster Group and operates in India with 19 hospitals, 13 clinics, 215 pharmacies, 232 labs, and patient experience centres across six states. QCIL manages a network of 26 healthcare centres with more than 5,150 beds in 14 cities. Its medical team comprises over 2,500 doctors and offers more than 30 specialities.

Conclusion

The approval from CCI clears the path for the formal merger process. Post-merger, the newly named Aster DM Quality Care Ltd. will bring together the operations of both companies under one entity.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.